152
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Efficacy and nephrotoxicity associated with various colistin dosing schemas for the treatment of multidrug resistant (MDR) infections

&
Pages 472-475 | Received 03 Nov 2017, Accepted 22 Nov 2017, Published online: 12 Dec 2017

References

  • Nazer LH, Rihani S, Hawari FI, et al. High-dose colistin for microbiologically documented serious respiratory infections associated with carbapenem-resistance Acinetobacter baumanii in critically ill cancer patients: a retrospective cohort study. Infect Dis (London). 2015;47:755–760.
  • Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
  • Imberti R, Cusato M, Villiani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333–1339.
  • Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin. Int J Antimicrob Agents. 2005;26:505–507.
  • Lee Y, Wi YM, Kwon YJ, et al. Association between colistin dose and development of nephrotoxicity. Crit Care Med. 2015;43:1187–1193.
  • Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: a comparative study of a matched series. Chemotherapy. 2016;61:190–196.
  • Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720–1726.
  • Phe K, Lee Y, McDaneld PM, et al. Comparison of nephrotoxicity rates associated with colistimethate versus polymyxin B therapy: in vitro assessment and a multicenter cohort study. Antimicrob Agents Chemother. 2014;58:2740–2746.
  • Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there Any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61:1–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.